Bard to sell TheraSeed in US:
This article was originally published in Clinica
Executive Summary
CR Bard is to distribute Theragenics' TheraSeed, for the treatment of prostate cancer and other solid localised cancerous tumours, in the US, Canada and Puerto Rico, under a five-year, non-exclusive agreement. Bard says the deal complements its leadership goal in the brachytherapy market.